AKT1 and glioblastoma: Our mechanistic studies show that SMARCC2 represses the expression of the oncogene DKK1 by stabilizing the SWI/SNF complex at the promoters of genes throughout the genome of GBM cell lines, which in turn inhibits cell proliferation through the PI3K–AKT pathway, suggesting that SMARCC2 is a potential target for the treatment of glioblastoma.